Metoclopramide G.L. Pharma (Metoclopramide Hydrochloride)

Metoclopramide works by blocking dopamine D2 receptors in the chemoreceptor trigger zone and the gastrointestinal tract, which reduces nausea signals. It also antagonizes 5‑HT3 receptors and stimulates 5‑HT4 receptors, enhancing acetylcholine release and promoting coordinated gastric motility.

The appropriate dose of Metoclopramide is determined by the prescribing clinician based on the patient’s condition, age, renal and hepatic function, and other individual factors. Dosage regimens are not standardized in this description and must follow the prescriber’s order.

Metoclopramide is classified as pregnancy category B1, indicating no evidence of risk in animal studies but limited human data. It may be used during pregnancy only if the potential benefit justifies the risk. Small amounts are excreted in breast milk; breastfeeding decisions should be made with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metoclopramide differs from many antiemetics by combining dopamine antagonism with serotonergic activity and pro‑kinetic effects. Unlike pure 5‑HT3 antagonists, it also enhances gastric motility, making it useful for gastroparesis. However, it carries a higher risk of extrapyramidal side effects compared with agents such as ondansetron.

Metoclopramide G.L. Pharma should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed when not in use.

Metoclopramide G.L. Pharma is supplied for intravenous injection. It is administered by a qualified healthcare professional, typically as a slow IV push or infusion, according to the prescriber’s instructions and the patient’s clinical condition.

The most serious risks include the development of tardive dyskinesia with prolonged use, neuroleptic malignant syndrome, severe depression or suicidal thoughts, seizures, and allergic reactions such as anaphylaxis. Patients should be monitored closely for any of these events, especially during high‑dose or long‑term therapy.

Metoclopramide is contraindicated in patients with known hypersensitivity to the drug, those with pheochromocytoma, and individuals with a history of severe extrapyramidal reactions. Caution is also advised for patients with gastrointestinal obstruction, perforation, or hemorrhage, as the drug may exacerbate these conditions.